68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

J.W Valle,S Qin,L Antonuzzo,D Tougeron,C-K Lee,B.J Tan,M Ikeda,V Guthrie,P Mccoon,Y.S Lee,N Rokutanda,M Żotkiewicz,G Cohen,D-Y Oh

doi:10.1016/j.annonc.2022.10.104

68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

J.W Valle, S Qin + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.104

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
Citations: 8	License type: publisher-specific-oa

Affiliation: University of Manchester, The Christie NHS Foundation Trust, Nanjing Brain Hospital, University of Poitiers, Yonsei University, National Cancer Center Hospital East, Seoul National University

#Advanced Biliary Tract Cancer #Biliary Tract Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In the double-blind, Phase 3 TOPAZ-1 study (NCT03875235), overall survival (OS) with D+GC versus PBO+GC was significantly improved in patients (pts) with previously untreated advanced BTC (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). An exploratory objective of the TOPAZ-1 study was to assess efficacy outcomes by tumour mutations.

Full Text